Ezra Cohen to Pyridines
This is a "connection" page, showing publications Ezra Cohen has written about Pyridines.
Connection Strength
1.201
-
Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013 Jun 01; 19(11):3059-67.
Score: 0.374
-
Cabozantinib for the treatment of advanced medullary thyroid cancer. Adv Ther. 2012 Nov; 29(11):925-34.
Score: 0.363
-
Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Cancer. 2016 Dec 15; 122(24):3856-3864.
Score: 0.118
-
Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10; 31(29):3639-46.
Score: 0.096
-
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6.
Score: 0.082
-
Novel molecular targeted therapies for refractory thyroid cancer. Head Neck. 2012 May; 34(5):736-45.
Score: 0.082
-
Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line. Dis Esophagus. 2008; 21(6):514-21.
Score: 0.065
-
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. Clin Cancer Res. 2011 Apr 01; 17(7):1956-63.
Score: 0.020